neurokinin-1 antagonist

(redirected from NK1 receptor antagonist)
Also found in: Wikipedia.

neurokinin-1 antagonist (NK1),

agent that blocks the action of substance Pm which is a peptide found in the brain and GI tract, which initiates its actions by binding to the neurokinin-1 receptor. Antagonists of the neurokinin-1 receptor have been shown to have antiemetic activity.
See also: substance P.
References in periodicals archive ?
The company added that the CINVANTI (aprepitant) injectable emulsion for intravenous (IV) use is the first and only polysorbate 80-free, IV formulation of an NK1 receptor antagonist (RA) indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
AKYNZEO is an oral fixed combination product, composed by a highly-selective NK1 receptor antagonist, netupitant, and palonosetron, the pharmacologically and clinically distinct 5-HT3 receptor antagonist which prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Aprepitant is an oral NK1 receptor antagonist approved as Emend more than a decade ago for prevention of chemotherapy-induced nausea and vomiting.
The filing of the NDA for CINVANTI is an important milestone, bringing us one step closer to a new NK1 receptor antagonist treatment option for cancer patients suffering from the debilitating side effects of chemotherapy, said Kimberly J.
Aprepitant is a highly selective NK1 receptor antagonist with little to no affinity for other neurokinin receptors [10,11].
"Effects of CP-99, 994, a tachykinin NK1 receptor antagonist, on abdominal afferent vagal activity in ferrets: Evidence for involvement of NK1 and 5-HT3 receptors." European Journal of Pharmacology 428.2 (2001): 215-220.
Akynzeo targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV.
It is composed of a highly-selective NK1 receptor antagonist, netupitant, and palonosetron, the pharmacologically and clinically distinct 5-HT3 receptor antagonist which prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Since its inception, Helsinn has built a comprehensive portfolio of market-leading products, such as Aloxi, the market-leading treatment for chemotherapy induced nausea and vomiting (CINV) and the next generation Akynzeo, the first approved fixed combination oral agent that targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV.
Privately held Menlo Therapeutics is focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatological conditions, and for refractory chronic cough.
It combines palonosetron with netupitant, the new highly selective NK1 receptor antagonist, in a single capsule.
AKYNZEO is the first fixed combination oral agent that targets two distinct signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule.